Quantcast
Get breaking news alerts via email

Click here to manage your alerts
Federal rulings set stage for BYU-Pfizer trial in Utah

First Published Mar 27 2012 07:09 pm • Last Updated Mar 27 2012 11:58 pm

A federal judge in Utah has issued a series of rulings that set the stage for a gigantic legal battle between Brigham Young University and Pfizer Inc. — potentially the largest civil trial in Utah history.

The rulings by U.S. District Judge Ted Stewart resolved legal questions in advance of the trial over BYU’s lawsuit that is scheduled to begin in late May. The Provo school claims that Pfizer reneged on a contract and misappropriated research from professor Daniel Simmons that led to the creation of the anti-inflammatory drug Celebrex, a "super aspirin" that is one of the most successful commercial drugs ever.

At a glance

BYU-Pfizer trial

What » A BYU lawsuit claims Pfizer misappropriated research of professor Dan Simmons

When » Trial scheduled to start May 29

Where » Federal courthouse, Salt Lake City

Length » At least six weeks

At stake » BYU claims it is owed at least $9.25 billion

Join the Discussion
Post a Comment

At stake are billions of dollars that BYU claims are owed it as compensation for Simmons’ contributions to the creation of Celebrex, which BYU says had sales of more than $33 billion. BYU says it is owed at least $9.25 billion in royalties from the Celebrex sales. Pfizer reported a profit of $8.7 billion last year.

Stewart’s rulings of the past two weeks have generally favored BYU, allowing it to bring its major allegations to a jury in a marathon trial scheduled to run for six weeks.

David Thomas, deputy general counsel at BYU, said the school was pleased that Stewart allowed the jury to hear evidence that Simmons should be listed as a co-inventor on patents that Pfizer obtained as part of its development of Celebrex.

"The ruling on Dr. Simmons’ co-inventorship claim is particularly gratifying because, if the jury embraces BYU’s evidence, Celebrex can become much more affordable," he said in a statement.

A verdict favorable to BYU could allow other companies to make versions of Celebrex.

Pfizer spokesman Christopher Loder said the "rulings are not ultimate rulings on the merits of either party’s case. While the company is pleased with some of the recent rulings and disappointed by others, it remains confident that the evidence at trial will show this lawsuit has no merit."

The lawsuit, filed nearly six years ago, contends that after Simmons came to BYU, he discovered a previously unknown enzyme. Starting in 1991, Simmons provided his research to Monsanto, which later was acquired by Pfizer, with the understanding Simmons would direct research into his COX-2 enzyme in order to create a commercial anti-inflammation product. BYU and Simmons were to share the patents and profits.

Instead, the suit alleges, Monsanto’s chief scientific officer, Philip Needleman, along with the company and its successors created a "COX-2 Project Enterprise" that appropriated the BYU professor’s research to create Celebrex and cut out the school and the BYU researcher.


story continues below
story continues below

Pfizer made it appear its own research led to the creation of the anti-inflammatory drug, even though it could not have done so without Simmons’ discoveries, the suit says.

"Dr. Simmons contracted with Pfizer’s predecessor, Monsanto, to share this discovery and provide biological materials," Thomas said Tuesday. "Monsanto misappropriated those biological materials and used them to redirect its steroid research to the non-steroidal anti-inflammatory research that resulted in Celebrex, whose sales have exceeded $33 billion."

Loder said Monsanto "met all of its obligations under the agreement. Years later, BYU and Dr. Simmons made unfounded allegations against Pfizer in an effort to capitalize on the company’s commercial success."

tharvey@sltrib.com

Twitter: TomHarveySltrib



Copyright 2014 The Salt Lake Tribune. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Top Reader Comments Read All Comments Post a Comment
Click here to read all comments   Click here to post a comment


About Reader Comments


Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Staying Connected
Videos
Jobs
Contests and Promotions
  • Search Obituaries
  • Place an Obituary

  • Search Cars
  • Search Homes
  • Search Jobs
  • Search Marketplace
  • Search Legal Notices

  • Other Services
  • Advertise With Us
  • Subscribe to the Newspaper
  • Login to the Electronic Edition
  • Frequently Asked Questions
  • Contact a newsroom staff member
  • Access the Trib Archives
  • Privacy Policy
  • Missing your paper? Need to place your paper on vacation hold? For this and any other subscription related needs, click here or call 801.204.6100.